The BioWorld Biopharmaceutical Index (BBI) ended 2024 down 2.24%, despite hitting a peak of 25.19% in late August. While it ...

Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report)‘s stock had its “buy” rating reissued by equities researchers at ...

Vilobelimab is being developed for various debilitating or life-threatening inflammatory indications, including a Phase 3 trial for pyoderma gangrenosum (PG). Vilobelimab has been granted orphan drug ...

Advances Pacira’s “5x30” path to becoming an innovative biopharmaceutical organization ---- Adds novel, high-capacity, local-delivery platform ...

European equities traded in the US as American depositary receipts were moving higher late Friday morning, up 0.48% to 1,412.34 on the S&P Europe Select ADR Index, which is relatively flat for the ...

(NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that SINOVAC has received on February 8, 2025 a formal court order (the “Order”) ...

Date and Time: Monday, March 10, 2025 at 1:40 p.m. Eastern time About Keros Therapeutics, Inc.

Ieq Capital LLC purchased a new position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Free Report) during the ...

Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...